carmustine has been researched along with Lymphoma, B-Cell in 30 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas." | 5.15 | (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. ( Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H, 2011) |
| " The experimental programme was safe and active in a multicentre setting, with only two episodes of grade 4 non-haematological toxicity (hepatotoxicity and mucositis), and no cases of systemic fungal infections; two patients died of toxicity (bacterial infections)." | 3.01 | A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. ( Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L, 2021) |
| "LDE-carmustine was shown to be safe and effective in a drug combination protocol, which encourages larger studies to investigate the use of this novel formulation to treat canine lymphomas." | 2.80 | Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma. ( Barboza, R; Coelho, BM; Guerra, JL; Lucas, SR; Maranhão, RC; Pozzi, DH, 2015) |
| "To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation." | 2.74 | Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. ( Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009) |
| "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy." | 1.32 | Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. ( Chen, CL; Chiu, CF; Chow, KC; Liaw, YC; Shen, YC; Yeh, SP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJM | 1 |
| Cattaneo, C | 1 |
| Lleshi, A | 1 |
| Verga, L | 1 |
| Allione, B | 1 |
| Facchetti, F | 1 |
| Ponzoni, M | 1 |
| Foppoli, M | 1 |
| Ferrari, D | 1 |
| Rigacci, L | 1 |
| Pecciarini, L | 1 |
| Donadoni, G | 1 |
| Fumagalli, L | 1 |
| Sassone, M | 1 |
| Calimeri, T | 1 |
| Rossi, G | 1 |
| Spina, M | 1 |
| Re, A | 1 |
| Ciochetto, C | 1 |
| Botto, B | 1 |
| Passera, R | 1 |
| Bellò, M | 1 |
| Benevolo, G | 1 |
| Boccomini, C | 1 |
| Castellino, A | 1 |
| Chiappella, A | 1 |
| Freilone, R | 1 |
| Nicolosi, M | 1 |
| Orsucci, L | 1 |
| Pecoraro, C | 1 |
| Pregno, P | 1 |
| Bisi, G | 1 |
| Vitolo, U | 1 |
| Cairo, M | 1 |
| Auperin, A | 1 |
| Perkins, SL | 1 |
| Pinkerton, R | 1 |
| Harrison, L | 1 |
| Goldman, S | 1 |
| Patte, C | 1 |
| Farnault, L | 1 |
| Venton, G | 1 |
| Pourroy, B | 1 |
| Jourde-Chiche, N | 1 |
| Ivanov, V | 1 |
| Arcani, R | 1 |
| Roche, P | 1 |
| Mercier, C | 1 |
| Colle, J | 1 |
| Fanciullino, R | 1 |
| Costello, RT | 1 |
| Lucas, SR | 1 |
| Maranhão, RC | 1 |
| Guerra, JL | 1 |
| Coelho, BM | 1 |
| Barboza, R | 1 |
| Pozzi, DH | 1 |
| Pytlík, R | 1 |
| Belada, D | 1 |
| Kubáčková, K | 1 |
| Vášová, I | 1 |
| Kozák, T | 1 |
| Pirnos, J | 1 |
| Bolomská, I | 1 |
| Matuška, M | 1 |
| Přibylová, J | 1 |
| Campr, V | 1 |
| Burešová, L | 1 |
| Sýkorová, A | 1 |
| Berková, A | 1 |
| Klener, P | 1 |
| Trněný, M | 1 |
| Kirschey, S | 1 |
| Flohr, T | 1 |
| Wolf, HH | 1 |
| Frickhofen, N | 1 |
| Gramatzki, M | 1 |
| Link, H | 1 |
| Basara, N | 1 |
| Peter, N | 1 |
| Meyer, RG | 1 |
| Schmitz, N | 1 |
| Weidmann, E | 1 |
| Banat, A | 1 |
| Schulz, A | 1 |
| Kolbe, K | 1 |
| Derigs, G | 1 |
| Theobald, M | 1 |
| Hess, G | 1 |
| Winter, JN | 1 |
| Inwards, DJ | 1 |
| Spies, S | 1 |
| Wiseman, G | 1 |
| Patton, D | 1 |
| Erwin, W | 1 |
| Rademaker, AW | 1 |
| Weitner, BB | 1 |
| Williams, SF | 1 |
| Tallman, MS | 1 |
| Micallef, I | 1 |
| Mehta, J | 1 |
| Singhal, S | 1 |
| Evens, AM | 1 |
| Zimmer, M | 1 |
| Molina, A | 1 |
| White, CA | 1 |
| Gordon, LI | 1 |
| Hohloch, K | 1 |
| Sahlmann, CO | 1 |
| Lakhani, VJ | 1 |
| Wulf, G | 1 |
| Glass, B | 1 |
| Hasenkamp, J | 1 |
| Meller, J | 1 |
| Riggert, J | 1 |
| Trümper, L | 1 |
| Griesinger, F | 1 |
| Decaudin, D | 1 |
| Mounier, N | 1 |
| Tilly, H | 1 |
| Ribrag, V | 1 |
| Ghesquières, H | 1 |
| Bouabdallah, K | 1 |
| Morschhauser, F | 1 |
| Coiffier, B | 1 |
| Le Gouill, S | 1 |
| Bologna, S | 1 |
| Delarue, R | 1 |
| Huynh, A | 1 |
| Bosly, A | 1 |
| Brière, J | 1 |
| Gisselbrecht, C | 2 |
| Wondergem, MJ | 1 |
| Zijlstra, JM | 1 |
| de Rooij, M | 1 |
| Visser, OJ | 1 |
| Huijgens, PC | 2 |
| Zweegman, S | 1 |
| Meyer, F | 1 |
| Buerger, T | 1 |
| Gebauer, T | 1 |
| Halloul, Z | 1 |
| Blystad, AK | 1 |
| Delabie, J | 1 |
| Kvaløy, S | 1 |
| Holte, H | 1 |
| Vålerhaugen, H | 1 |
| Ikonomou, I | 1 |
| Kvalheim, G | 1 |
| Shen, YC | 1 |
| Chiu, CF | 1 |
| Chow, KC | 1 |
| Chen, CL | 1 |
| Liaw, YC | 1 |
| Yeh, SP | 1 |
| Wójcik, B | 1 |
| Kowalczyk, JR | 1 |
| Chybicka, A | 1 |
| Wachowiak, J | 1 |
| Drabko, K | 1 |
| Zaucha-Prazmo, A | 1 |
| Choma, M | 1 |
| Gorczyńska, E | 1 |
| Toporski, J | 1 |
| Turkiewicz, D | 1 |
| Kałwak, K | 1 |
| Pieczonka, A | 1 |
| Boruczkowski, D | 1 |
| Khouri, IF | 1 |
| Saliba, RM | 1 |
| Hosing, C | 1 |
| Okoroji, GJ | 1 |
| Acholonu, S | 1 |
| Anderlini, P | 2 |
| Couriel, D | 1 |
| De Lima, M | 2 |
| Donato, ML | 1 |
| Fayad, L | 1 |
| Giralt, S | 2 |
| Jones, R | 1 |
| Korbling, M | 1 |
| Maadani, F | 1 |
| Manning, JT | 1 |
| Pro, B | 1 |
| Shpall, E | 1 |
| Younes, A | 1 |
| McLaughlin, P | 1 |
| Champlin, RE | 1 |
| Crowther, H | 1 |
| Collins, D | 1 |
| Antonenas, V | 1 |
| McGurgan, M | 1 |
| Kerridge, I | 1 |
| Gottlieb, D | 1 |
| Bradstock, K | 1 |
| Hagberg, H | 1 |
| Keijzer, A | 1 |
| van de Loosdrecht, AA | 1 |
| Scheid, C | 1 |
| Pettengell, R | 1 |
| Ghielmini, M | 1 |
| Radford, JA | 1 |
| Morgenstern, GR | 1 |
| Stern, PL | 1 |
| Crowther, D | 1 |
| Popat, U | 1 |
| Przepiork, D | 1 |
| Champlin, R | 1 |
| Pugh, W | 1 |
| Amin, K | 1 |
| Mehra, R | 1 |
| Rodriguez, J | 1 |
| Romaguera, J | 1 |
| Rodriguez, A | 1 |
| Preti, A | 1 |
| Andersson, B | 1 |
| Khouri, I | 1 |
| Claxton, D | 1 |
| Donato, M | 1 |
| Gajewski, J | 1 |
| Cabanillas, F | 1 |
| van Besien, K | 1 |
| Peták, I | 1 |
| Mihalik, R | 1 |
| Bauer, PI | 1 |
| Süli-Vargha, H | 1 |
| Sebestyén, A | 1 |
| Kopper, L | 1 |
| Azaceta, G | 1 |
| Palomera, L | 1 |
| Varo, MJ | 1 |
| Soria, J | 1 |
| Popescu, RA | 1 |
| Wotherspoon, AC | 1 |
| Cunningham, D | 1 |
| Amigo, ML | 1 |
| del Cañizo, MC | 1 |
| Hernández, JM | 1 |
| Gonzalez, MB | 1 |
| Gutiérrez, N | 1 |
| Mateos, MV | 1 |
| San Miguel, JF | 1 |
| Krackhardt, A | 1 |
| Schwartz, S | 1 |
| Korfel, A | 1 |
| Thiel, E | 1 |
| Volk, J | 1 |
| Kleine, HD | 1 |
| Buthmann, U | 1 |
| Freund, M | 1 |
| Neumeister, P | 1 |
| Hoefler, G | 1 |
| Beham-Schmid, C | 1 |
| Sill, H | 1 |
| Linkesch, W | 1 |
| Davis, TA | 1 |
| Hsu, FJ | 1 |
| Caspar, CB | 1 |
| van Beckhoven, A | 1 |
| Czerwinsk, DK | 1 |
| Liles, TM | 1 |
| Taidi, B | 1 |
| Benike, CJ | 1 |
| Engleman, EG | 1 |
| Levy, R | 1 |
| Goldkuhl, C | 1 |
| Ekman, T | 1 |
| Wiklund, T | 1 |
| Telhaug, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006] | Phase 2 | 21 participants (Actual) | Interventional | 2014-07-09 | Terminated (stopped due to Insufficient recruitment and unavailability of the treatment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 trials available for carmustine and Lymphoma, B-Cell
| Article | Year |
|---|---|
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2021 |
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Car | 2018 |
Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, | 2015 |
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combin | 2011 |
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplast | 2011 |
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2005 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2006 |
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Antibodies, Anti-Idiotypic; Antibodies, N | 2001 |
Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervou | 2002 |
19 other studies available for carmustine and Lymphoma, B-Cell
| Article | Year |
|---|---|
Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Child; | 2018 |
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Humans; L | 2019 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu | 2015 |
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modalit | 2012 |
Unusual implantation site of a port-a-cath system via the right femoral vein.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; | 2002 |
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 2004 |
Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
Topics: Adult; Antineoplastic Agents, Alkylating; Carmustine; Cyclooxygenase 2; Fatal Outcome; Female; Human | 2004 |
[Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; | 2004 |
Successful autologous peripheral blood stem cell harvest and transplant in a patient with cold agglutinins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryoglobulins; Cytarabine; Humans; Lymph | 2006 |
Palifermin and palmar-plantar erythrodysesthesia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug | 2007 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; | 1995 |
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1998 |
BCNU is a caspase-mediated inhibitor of drug-induced apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Caspase 3; Caspases; Cysteine Endopeptidas | 1998 |
[Intensive treatment of T-cell-rich B lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 1998 |
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cy | 1998 |
Clonal myelodysplastic cells present in apheresis product before transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Aberrations; Chromosomes, Hum | 1998 |
Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 1999 |
Oxidative burst measurement in patients treated with cytostatics: influence of G-CSF and role as a prognostic factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine | 2000 |
Complete remission of generalized relapsed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type of the gastrointestinal tract after high-dose chemotherapy and autologous peripheral stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; D | 2000 |